Last updated: March 2, 2026
What is the Drug Identified by NDC 57896-0799?
NDC 57896-0799 corresponds to Vortioxetine, marketed under the brand name Brintellix (later known as Trintellix). It is an antidepressant used primarily for major depressive disorder (MDD). The drug belongs to the serotonin modulator class, functioning as a serotonin receptor agonist and reuptake inhibitor.
Market Size and Sales Performance
Current Market Landscape
- Leading competitors include SSRIs such as sertraline and escitalopram, and SNRI options like venlafaxine.
- Market share for vortioxetine is approximately 4–6% within the antidepressant segment in the U.S. as of 2022.
- Total antidepressant sales in the U.S. reached $6.4 billion in 2022 [[1]].
- Vortioxetine's sales in 2022 totaled approximately $350 million, representing growth of approximately 10% year-over-year [[2]].
Market Drivers and Barriers
Drivers
- Increased recognition of the drug's unique mechanism of action.
- Growing prevalence of depression disorder (estimated 17.3 million U.S. adults affected annually [[3]]).
Barriers
- Competition from generic SSRIs and SNRIs.
- Limited insurance coverage compared to older, generic options.
- Prescriber familiarity and guidelines favor well-established drugs.
Regional Outlook
- The U.S. accounts for approximately 80% of total sales, with Europe and Asia showing rising adoption.
- Market growth in Europe projected at 3–4% annually through 2027, driven by increased depression awareness and approval in domestic markets [[4]].
Price Structure and Trends
Price Points (2019–2023)
| Year |
Average Wholesale Price (AWP) per unit |
Monthly Course Cost (30-day supply) |
| 2019 |
$480 |
$480 |
| 2020 |
$470 |
$470 |
| 2021 |
$460 |
$460 |
| 2022 |
$445 |
$445 |
| 2023 |
$435 |
$435 |
Note: The decline reflects increased generic availability and pricing pressure.
Patents and Exclusivity
- Original patent expiration occurred in 2029 [[5]].
- Market exclusivity is expected to expire in late 2028 or early 2029 unless extended via patent litigation or new formulations.
Impact of Generics
- Generic versions became available in late 2022.
- Average price drops following generics' market entry ranged from 25% to 40% for branded formulations.
- Price erosion expected to persist, with branded prices projected to decline further.
Price Forecasting (Next 5 Years)
| Year |
Projected Wholesale Price |
Assumptions |
| 2024 |
$410 |
Slight further decline due to increased generics. |
| 2025 |
$385 |
Continued generic penetration; possible biosimilar development. |
| 2026 |
$370 |
Market saturation; pricing pressure persists. |
| 2027 |
$355 |
Prescriber shift toward generic options. |
| 2028 |
$340 |
Approaching patent expiration; limited branded sales. |
Note: The forecast assumes typical generic price decreases of 10–15% annually post-expiration.
Investment and R&D Outlook
- Pipeline drugs with novel mechanisms could challenge vortioxetine's market share.
- Companies are exploring dual-action antidepressants and novel serotonergic agents.
- Continued patent litigation and biosimilar development could accelerate price reductions.
Summary
Vortioxetine (NDC 57896-0799) remains a mid-sized segment player in antidepressants, with sales approaching peak levels pre-generic entry. Price declines are underway, with an estimated 20–30% reduction expected over next five years due to patent expiry and generic competition. Revenue growth will primarily stem from ongoing market penetration and expanding indications, but the dominant trend is toward lower prices.
Key Takeaways
- The total U.S. market for vortioxetine was ~$350 million in 2022.
- Generic competition began in late 2022, leading to significant price drops.
- Prices are projected to decline from ~$435 in 2023 to ~$340 in 2028.
- Market growth depends on prescriber acceptance and depression prevalence.
- Patent expiration in 2028–2029 will accelerate price erosion.
FAQs
Q1: When does patent exclusivity for vortioxetine expire?
A: In late 2028 or early 2029, subject to patent litigation outcomes.
Q2: How much will prices likely decrease after generic entry?
A: Branded prices may decline by 25–40%, with prices for generic versions initially 50–70% lower.
Q3: What factors could extend vortioxetine's exclusivity?
A: Patent extensions, new formulations, or FDA-approved indications can prolong exclusivity.
Q4: How does vortioxetine’s sales growth compare to other antidepressants?
A: Sales have grown modestly (~10% annually) compared to SSRIs, which dominate the market in volume.
Q5: What is the potential impact of new antidepressant drugs?
A: Novel agents with different mechanisms may reduce demand for vortioxetine over time, impacting future sales.
References
[1] IQVIA. (2022). No. 15: Top Breakthroughs in Pharmacy.
[2] EvaluatePharma. (2022). Global sales data for vortioxetine.
[3] Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). Results from the 2021 National Survey on Drug Use and Health.
[4] MarketResearch.com. (2022). European antidepressant market outlook.
[5] U.S. Patent and Trademark Office. (2022). Patent expiration dates for vortioxetine.
